> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Orphan Status for OBI Pharma Pancreatic Cancer Drug
- URL: https://www.fdaweb.com/orphan-status-for-obi-pharma-pancreatic-cancer-drug/
- Published: 2018-11-21T12:00:00.000Z
- Updated: 2026-09-15T00:46:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142881

FDA has granted OBI Pharma an Orphan Drug Designation for OBI-888 for treating pancreatic cancer. OBI-888 is a first-in-class monoclonal antibody cancer immunotherapy targeting Globo H, a glycolipid antigen. A Phase 1 study is underway at the University of Texas M.D. Anderson Cancer Center in patients with locally advanced or metastatic solid tumors, potentially including pancreatic, breast, gastric, esophageal, colorectal and lung cancers.